Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

Charitable programme: Cuttsy Cares

Cuttsy Cares Continues…

Cuttsy+Cuttsy's charitable programme — Cuttsy Cares — has been running for the past 2 years, providing the team with the opportunity to support causes close to their hearts.

Cuttsy + Cuttsy

B-lown away by our first CDP rating

A catch up with Louise Jones, Cuttsy+Cuttsy's sustainability officer, on what was achieved in 2022, the agency's latest environmental assessment with CDP and a look ahead to 2023.

Cuttsy + Cuttsy

- PMLiVE

The importance of creativity in content

By Louise Barry

- PMLiVE

Novo Nordisk and Aspect Biosystems partner in billion dollar deal for diabetes treatments

The deal to develop a new class of disease-modifying treatments could be worth up to $2.6bn

- PMLiVE

Incyte and Biotheryx collaborate to develop protein degraders for oncology targets

Biotheryx will receive up to $347m in potential milestone payments

- PMLiVE

Almirall becomes first to assess well-being as primary endpoint in dermatology study

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Onyx Health announces three new hires

Laura Waldron will be joining as account manager, Katy Johns as creative artworker, and Lewis Hutchinson as marketing communications trainee

Expanding Access to High-Quality Healthcare

Dr. Jason Cross, Co-founder & Chief Strategy Officer at Rymedi, dives into Connected Health, including how it can be used to expand access to high-quality healthcare, current barriers to its...

Impetus Digital

- PMLiVE

Merck and Proxygen partner in deal worth up to $2.5bn

The companies will identify molecular glue degraders against multiple therapeutic targets

- PMLiVE

NICE publishes draft guidance not recommending Ipsen’s Cabometyx for thyroid cancer

Up to 15% of patients with differentiated thyroid cancer do not respond to radioactive iodine

- PMLiVE

Sartorius signs agreement to acquire Polyplus for €2.4bn

The deal is expected to close during the third quarter of this year

- PMLiVE

Why diagnostics investments are crucial to win the AMR battle

AMR could take the lives of ten million people a year within three decades

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links